Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

Table 1 Relationship between IGFBP-3 expression and clinicopathology

Characteristic	IGFBP-3 score			P	No. of patients
	Negative	Weak (1+)	Strong (2+)
Invasive tumours	15	54	32		101*
Age (years)
≤ 50	1	13	13	0.04	27
> 50	14	41	19		74
Lymph node status
Negative	7	17	13	0.216	37
Positive	4	31	16		51
Not assessed					13
IDC grade
I	2	9	5	0.836	16
II	9	24	17		50
III	4	21	10		35
IDC size
≤ 2 cm	9	26	17	0.720	52
>2 cm	6	27	14		47
Multifocal					2
LV invasion
Absent	9	27	12	0.411	48
Present	6	26	18		50
Not assessed					3
NPI
GPG (< 3.4)	6	17	11	0.662	34
MPG (3.4–5.4)	4	19	13		36
PPG (> 5.4)	1	11	4		16
Not calculable					15
ER (quick-score)
Positive (4–8)	12	28	21	0.06	61
Negative (0–3)	2	24	9		35
Not assessed					7
HER-2 IHC
Negative (0/1+)	14	48	23	0.065	85
Positive (2+/3+)	1	6	9		16
Ki67 IHC
Low proliferation < 10%	10	26	13	0.249	49
High proliferation ≥ 10%	5	28	19		52
DCIS					102*
VNPC
Grade I	1	14	8	0.586	23
Grade II	5	17	14		36
Grade III	2	21	15		38
Not assessed					5
ER (quick-score)
Positive (4–8)	11	26	19	0.037	56
Negative (0–3)	1	23	9		33
Not assessed					13
HER-2 IHC
Negative (0/1+)	7	41	28	0.876	76
Positive (2+/3+)	2	9	8		19
Not assessed					7
Ki67 IHC
Low proliferation < 10%	6	30	24	0.972	60
High proliferation ≥ 10%	4	22	16		42

DCIS, ductal carcinoma in situ; ER, oestrogen receptor; GPG, good prognostic group; IHC, immunohistochemistry; MPG, moderate prognostic group; NPI, Nottingham Prognostic Index; PPG, poor prognostic group; VNPC, Van Nuys Pathologic classification. Significant P values (P < 0.05) are indicated in bold.
*Patient numbers reflect those in whom IGFBP-3 was evaluable.

ISSN: 1465-542X